🇺🇸 FDA

Intelligence · Clinical Pipeline

Novartis India Pipeline

All ClinicalTrials.gov programs at Novartis India — phase, modality, and trial IDs.

Programs
341

Quick answer

Novartis India has 341 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Indacaterol (QAB149)

    Novartis Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

  2. JSB462

    Novartis Pharmaceuticals

    Metastatic Prostate Cancer (mCRPC)

    phase 1 small molecule active

    1 trial

  3. KFA115

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule active

    1 trial

  4. LDK378

    Novartis Pharmaceuticals

    Anaplastic Lymphoma Kinase (ALK)

    phase 1 small molecule completed

    1 trial

  5. LDT600 (Telbivudine)

    Novartis Pharmaceuticals

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  6. LEE011

    Novartis Pharmaceuticals

    Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

    phase 1 small molecule completed

    1 trial

  7. LGH447

    Novartis Pharmaceuticals

    AML and High Risk MDS

    phase 1 small molecule completed

    1 trial

  8. LGH447

    Novartis Pharmaceuticals

    Relapsed and Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  9. Locametz 25 micrograms kit for radiopharmaceutical preparation, -, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Metastatic Castration-Resistant Prostate Cancer

    phase 1 small molecule active

    1 trial

  10. MBG453

    Novartis Pharmaceuticals

    Myelodysplastic Syndromes

    phase 1 small molecule terminated

    1 trial

  11. PDR001

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  12. PDR001

    Novartis Pharmaceuticals

    Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

    phase 1 mab completed

    1 trial

  13. Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  14. Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors

    Novartis Pharmaceuticals

    Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway

    phase 1 other active

    1 trial

  15. Phase I study of MGY825 in patients with lung cancer

    Novartis Pharmaceuticals

    Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients

    phase 1 other active

    1 trial

  16. Phase Ib Dose Finding Study of [177Lu]Lu-NeoB in Combination with RT and TMZ in Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma

    Novartis Pharmaceuticals

    Glioblastoma

    phase 1 other active

    1 trial

  17. QEQ278

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 1 mab terminated

    1 trial

  18. Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  19. Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  20. Study of PIT565 in relapsed and/or refractory B-cell malignancies

    Novartis Pharmaceuticals

    Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

    phase 1 other active

    1 trial

  21. Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

    Novartis Pharmaceuticals

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  22. Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  23. Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL

    Novartis Pharmaceuticals

    Relapsed/refractory Non Hodgkin Lymphoma

    phase 1 other active

    1 trial

  24. Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

    Novartis Pharmaceuticals

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial

  25. -, IPTACOPAN, -, -, -

    Novartis Pharmaceuticals

    IgA Nephropathy

    approved small molecule active

    1 trial

  26. Aliskiren

    Novartis Pharmaceuticals

    Hypertension

    approved small molecule completed

    1 trial

  27. CERITINIB

    Novartis Pharmaceuticals

    non small cell lung cancer

    approved small molecule active

    1 trial

  28. Enteric-Coated Mycophenolate Sodium (EC-MPS)

    Novartis Pharmaceuticals

    Renal Transplant

    approved small molecule completed

    1 trial

  29. Fluvirin(TIVf)

    Novartis Pharmaceuticals

    Influenza

    approved mab completed

    1 trial

  30. INCLISIRAN SODIUM, BEMPEDOIC ACID, ATORVASTATIN, ROSUVASTATIN, EZETIMIBE

    Novartis Pharmaceuticals

    Hypercholesterolemia

    approved small molecule active

    1 trial

  31. IPTACOPAN HYDROCHLORIDE, IPTACOPAN

    Novartis Pharmaceuticals

    C3 Glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis

    approved small molecule active

    1 trial

  32. Indacaterol

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    approved small molecule completed

    1 trial

  33. Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, Jakavi 20 mg tablets, Jakavi 5 mg tablets, HDM201, RUXOLITINIB, Jakavi 20 mg tablets, Farydak 15 mg hard capsules, Jakavi 10 mg tablets, Jakavi 15 mg tablets, Jakavi 5 mg tablets, Farydak 10 mg hard capsules, Jakavi 10 mg tablets, Jakavi 15 mg tablets, HDM201, Jakavi 20 mg tablets

    Novartis Pharmaceuticals

    This study is designed to accept patients with varied disease origins, depending on the parent protocol

    approved small molecule active

    1 trial

  34. Kesimpta 20 mg solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Relapsing forms of Multiple Sclerosis (RMS)

    approved small molecule active

    1 trial

  35. LETROZOLE, RIBOCICLIB, GOSERELIN ACETATE, LEE011, TAMOXIFEN

    Novartis Pharmaceuticals

    HR+, HER2- advanced or metastatic breast cancer

    approved small molecule active

    1 trial

  36. Mekinist, DRB436, DRB436, TMT212, TMT212, Mekinist 0.5 mg film-coated tablets, DRB436, Mekinist 2 mg film-coated tablets

    Novartis Pharmaceuticals

    Children and Adolescents with Cancers Harboring V600 mutation.

    approved small molecule active

    1 trial

  37. Neovascular Age-related Macular Degeneration

    Novartis Pharmaceuticals

    Neovacular Age-related Macular Degeneration

    approved other completed

    1 trial

  38. Ofatumumab

    Novartis Pharmaceuticals

    Relapsing Multiple Sclerosis

    approved mab completed

    1 trial

  39. Placebo of vildagliptin

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  40. Placebo to AIN457 150 mg/1 mL Solution for injection in pre-filled syringe, SECUKINUMAB

    Novartis Pharmaceuticals

    non-radiographic axial spondyloarthritis

    approved small molecule active

    1 trial

  41. Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Prostate cancer

    approved small molecule active

    1 trial

  42. ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, INCLISIRAN

    Novartis Pharmaceuticals

    Hypercholesterolemia

    approved small molecule active

    1 trial

  43. Ribociclib

    Novartis Pharmaceuticals

    Metastatic Breast Cancer

    approved small molecule active

    1 trial

  44. Rivastigmine

    Novartis Pharmaceuticals

    Alzheimer's Disease

    approved small molecule completed

    1 trial

  45. Rivastigmine transdermal patch

    Novartis Pharmaceuticals

    Alzheimer's Disease

    approved small molecule completed

    1 trial

  46. SEG101

    Novartis Pharmaceuticals

    Sickle cell disease

    approved small molecule active

    1 trial

  47. Secukinumab s.c. injection

    Novartis Pharmaceuticals

    Autoimmunity, Inflammation

    approved mab active

    1 trial

  48. TMT212, TMT212, Mekinist 0.5 mg film-coated tablets, Mekinist 2 mg film-coated tablets, DRB436, DRB436, DRB436, TMT212

    Novartis Pharmaceuticals

    Multiple indications

    approved small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Novartis India have?

341 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.